This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"

Recifercept is the name  Pfizer has selected for the orphan drug for achondroplasia. Pfizer acquired Therachon in May 2019 (Pfizer press release here) and with that, TA-46, the molecule being developed as a potential treatment for achondroplasia. The acquisition process was concluded in September 2019, and now the company is has listed the new name at their Pipeline page. Both "Therachon" and "TA-46" are no longer in use. 

ReciferceptFigure 1. Pfizer Rare Diseases Pipeline & Trials.

Pfizer has an increased potential to deliver an effective trial, based on the experience, structure, logistical and financial strengths of the company.  New information regarding the Phase 2 clinical trial is expected to be disclosed soon.

Nevertheless, is still time to remember the excellent work that was achieved by Therachon team with the development of the soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy, that as the potential to reduce the complications in achondroplasia, with a high safety profile (based on existent pre-clinical information).
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.